Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces

Miguel A González-Gay; José Mayo; Santos Castañeda; José M Cifrián; José Hernández-Rodríguez

doi:10.1080/14712598.2020.1770222

Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces

Expert Opin Biol Ther. 2020 Jul;20(7):717-723. doi: 10.1080/14712598.2020.1770222. Epub 2020 Jun 4.

Authors

Miguel A González-Gay^{1

2

3}, José Mayo⁴, Santos Castañeda⁵, José M Cifrián⁶, José Hernández-Rodríguez⁷

Affiliations

¹ Division of Rheumatology and Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain.
² University of Cantabria , Santander, Spain.
³ Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg, South Africa.
⁴ Infectious Diseases Unit, Galdakao-Usansolo Hospital , Galdakao, Bizkaia, Spain.
⁵ Rheumatology Division, Hospital de La Princesa, IIS-Princesa, Cátedra UAM-Roche, EPID Future, Universidad Autónoma de Madrid (UAM) , Madrid, Spain.
⁶ Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL , Santander, Spain.
⁷ Vasculitis Research Unit and Clinical Unit of Autoinflammatory Diseases, Department of Autoimmune Diseases, Hospital Clínic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) , Barcelona, Spain.

No abstract available

Keywords: COVID-19; Chimeric antigen receptor (CAR) T cell‐induced cytokine release syndrome; anakinra; colchicine; coronavirus; inflammation; interleukin-6; macrophage activation syndrome; tocilizumab.

Publication types

Editorial

Grants and funding

This paper is not funded.